Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 218Magnetic Resonance Spectroscopy 194pembrolizumab 185Carboplatin 160Biopsy 129Cisplatin 128Nivolumab 119Paclitaxel 107Cyclophosphamide 104Radiotherapy 99Gemcitabine 96Dexamethasone 86durvalumab 83atezolizumab 70Rituximab 66Radiation 64Lenalidomide 64Doxorubicin 63Pemetrexed 61Bevacizumab 58Etoposide 56Docetaxel 56olaparib 50Ipilimumab 49Fluorouracil 48Taxes 47Prednisone 47Oxaliplatin 46Vincristine 45Cytarabine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × cc-486 × 90 days × Clear all
NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT05413018 2026-04-28

An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission

Bristol-Myers Squibb

Phase 2 Active not recruiting
34 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡